- Unyango
- Ubungqina
- I-Neuroblastoma
- Ithumba Eliqinileyo
- Ubungqina
- Ii-TILS
- Unyango lweeSeli zeNK
- I-Myasthenia Gravis (MG)
- I-Acute Lymphoblastic Leukemia (B-ALL)
- I-Systemic Lupus Erythematosus (SLE)
- I-Acute Lymphoblastic Leukemia (T-ALL)
- I-NonHodgkin Lymphoma (NHL)
- I-Multiple Myeloma（MM）
- Ukusasaza i-B-cell Lymphom enkulu
- I-B-lymphocytic Leukemia
- I-Myeloma
Umhlaza wemiphunga ongengoweeseli ezincinci (i-NSCLC)-02
Isigulana esiyindoda esineminyaka engama-82 ubudala saqala ukubonakala ekuqaleni kukaMatshi 2023 sinobuthathaka obuqhubekayo, ukuphelelwa ngumdla wokutya, kunye nokwehla kobunzima obumalunga neekhilogram ezi-5. Emva kokungeniswa, kwenziwa uhlolo oluneenkcukacha. I-CT scan yesifuba yabonisa amaqhuqhuva amaninzi kwimiphunga yomibini, enkulu imalunga ne-2.5 cm. Iqhuqhuva elikhulu kwicandelo le-apical lobe esezantsi ngasekunene kunye neqhuqhuva elikhulu kwicandelo le-dorsal lobe engasentla ngasekhohlo zombini zazinemida engacacanga. Emva kovavanyo lwe-biopsy yesifuba kunye ne-pathological, ukuxilongwa komhlaza wemiphunga ongengowe-cell encinci (i-NSCLC) kwaqinisekiswa, kunye ne-adenocarcinoma ekhoyo kwicandelo le-dorsal lobe engasentla ngasekhohlo kunye necandelo le-apical lobe esezantsi ngasekunene.
Emva koko isigulana safumana irejimeni ye-immunotherapy yeseli ye-NK. Emva kwenyanga yokuqala yonyango, uvavanyo olulandelayo alubonisanga tshintsho lubalulekileyo kubukhulu bee-nodules zemiphunga, kodwa iimpawu zesigulana ngokubanzi zaziphucukile, kunye nobuthathaka obunciphileyo kunye nokubuyela kancinci kokutya. Emva kwenyanga yesibini yonyango, olunye uvavanyo lwe-CT yesifuba lubonise umda ocacileyo kunye nokuncipha okuncinci kobukhulu be-nodule kwicandelo le-apical le-lobe esezantsi yasekunene, kunye ne-necrosis engaphelelanga kunye nomzobo ocacileyo we-nodule kwicandelo le-dorsal le-lobe ephezulu yasekhohlo. Emva kwenyanga yesithathu yonyango, i-CT yesifuba ibonise ukwehla okungakumbi kubukhulu bee-nodules kwimiphunga yomibini, kunye ne-nodule enkulu ngoku engadluli kwi-1.5 cm, ukufunxwa kwezilonda zemiphunga, kunye nokuphucuka okuphawulekayo kweklinikhi.
Ngamafutshane, unyango lwe-NK cell immunotherapy lubonakalise ukusebenza kakuhle kunye nokunyamezeleka kwesi sigulana sineminyaka engama-82 ubudala esine-NSCLC, kunye nokuncipha okukhulu kwezilonda zemiphunga kunye nokuphucuka okukhulu kwimeko iyonke yesigulana. Ukulandelela kunye nezicwangciso zonyango ezongezelelweyo ziya kuqhubeka nokujonga ukuqhubela phambili kwesifo kunye nemiphumo yonyango.
inkcazo2